RNXT Key Statistics, Chart & Performance
The current stock price of RNXT is 0.96 USD. In the past month the price increased by 9.76%. In the past year, price decreased by -29.41%.
RNXT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RNXT. When comparing the yearly performance of all stocks, RNXT is a bad performer in the overall market: 85.43% of all stocks are doing better.
RNXT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RNXT. RNXT has a great financial health rating, but its profitability evaluates not so good.
RNXT Financial Highlights
Over the last trailing twelve months RNXT reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS increased by 36.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -99.1% | ||
| ROE | -137.47% | ||
| Debt/Equity | 0 |
RNXT Forecast & Estimates
10 analysts have analysed RNXT and the average price target is 5.74 USD. This implies a price increase of 497.66% is expected in the next year compared to the current price of 0.96.
RNXT Ownership
RNXT Latest News, Press Relases and Analysis
About RNXT
Company Profile
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. The company is headquartered in Mountain View, California and currently employs 10 full-time employees. The company went IPO on 2021-08-17. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
Company Info
RENOVORX INC
2570 W. El Camino Real, Ste. 320,
Mountain View CALIFORNIA US
CEO: Shaun R. Bagai
Employees: 10
Phone: 14088002649
RENOVORX INC / RNXT FAQ
What does RENOVORX INC do?
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. The company is headquartered in Mountain View, California and currently employs 10 full-time employees. The company went IPO on 2021-08-17. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
What is the current price of RNXT stock?
The current stock price of RNXT is 0.96 USD. The price increased by 6.56% in the last trading session.
Does RNXT stock pay dividends?
RNXT does not pay a dividend.
What is the ChartMill rating of RENOVORX INC stock?
RNXT has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of RENOVORX INC (RNXT) based on its PE ratio?
RENOVORX INC (RNXT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).
Is RENOVORX INC (RNXT) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RNXT.
What is the market capitalization of RNXT stock?
RENOVORX INC (RNXT) has a market capitalization of 35.18M USD. This makes RNXT a Nano Cap stock.